Skip to main content
Erschienen in: Der Onkologe 11/2010

01.11.2010 | Leitthema

Stellenwert der Hyperthermie im Rahmen der medikamentösen Tumortherapie

verfasst von: PD Dr. L.H. Lindner, R.D. Issels

Erschienen in: Die Onkologie | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der klinisch innovative Therapieansatz der Hyperthermie in Kombination mit Chemotherapie gründet sich auf Erkenntnisse der Grundlagenforschung. Der biologische Effekt der Temperaturerhöhung auf Tumorzellen folgt einem Dosis-Wirkungs-Prinzip und ist gemessen am klonogenen Wachstum in mathematischer Systembeschreibung auch quantifizierbar. Für die sowohl in vitro als auch in vivo nachweisbare Thermosensibilisierung von Tumorzellen mit Folge einer Effektivitätssteigerung von definierten Zytostatika sind neben der Temperaturdosis insbesondere die Sequenz und das Zeitintervall von Bedeutung. Klinische Ergebnisse aus Phase-II/III-Studien zeigen für die Kombination mit Chemotherapie z. T eine signifikante Verbesserung der lokalen Tumorkontrolle und in einigen Studien auch einen Anstieg der krankheitsfreien Überlebenszeit. Zur weiteren Definition des Stellenwerts der Hyperthermie für die multimodale Behandlung von Tumorerkrankten sollten Patienten in randomisierte Studien eingeschlossen werden.
Literatur
1.
Zurück zum Zitat Atmaca A, Al Batran SE, Neumann A et al (2009) Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer – A phase II study. Gynecol Cancer 112:384–388CrossRef Atmaca A, Al Batran SE, Neumann A et al (2009) Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer – A phase II study. Gynecol Cancer 112:384–388CrossRef
2.
Zurück zum Zitat Bauer KD, Henle KJ (1979) Arrhenius analysis of heat survival curves from normal and thermotolerant CHO cells. Radiat Res 78:251–263CrossRefPubMed Bauer KD, Henle KJ (1979) Arrhenius analysis of heat survival curves from normal and thermotolerant CHO cells. Radiat Res 78:251–263CrossRefPubMed
3.
Zurück zum Zitat Colombo R, Da Pozzo LF, Salonia A et al (2003) Multicentric study comparing intraveiscal chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 21:4270–4276CrossRefPubMed Colombo R, Da Pozzo LF, Salonia A et al (2003) Multicentric study comparing intraveiscal chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 21:4270–4276CrossRefPubMed
4.
Zurück zum Zitat Dahl O (1988) Interaction of hyperthermia and chemotherapy. Recent Results Cancer Res 107:157–169PubMed Dahl O (1988) Interaction of hyperthermia and chemotherapy. Recent Results Cancer Res 107:157–169PubMed
5.
Zurück zum Zitat Dewey WC (1994) Arrhenius relationships from the molecule and cell to clinic. Int J Hyperthermia 10:457–483CrossRefPubMed Dewey WC (1994) Arrhenius relationships from the molecule and cell to clinic. Int J Hyperthermia 10:457–483CrossRefPubMed
6.
Zurück zum Zitat Fiegl M, Schlemmer M, Wendtner CM et al (2004) Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. Int J Hyperthermia 20:661–670CrossRefPubMed Fiegl M, Schlemmer M, Wendtner CM et al (2004) Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults. Int J Hyperthermia 20:661–670CrossRefPubMed
7.
Zurück zum Zitat Fotopoulou C, Cho CH, Kraetschell R et al (2010) Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study. Int J Hyperthermia 26:118–126CrossRefPubMed Fotopoulou C, Cho CH, Kraetschell R et al (2010) Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study. Int J Hyperthermia 26:118–126CrossRefPubMed
8.
Zurück zum Zitat Franckena M, Wit R de, Ansink AC et al (2007) Weekly systemic cisplatin plus locoregional hyperthermia: An effective treatment for patients with recurrent cervical carcinoma in a previously irradiated area. Int J Hyperthermia 23:443–450CrossRefPubMed Franckena M, Wit R de, Ansink AC et al (2007) Weekly systemic cisplatin plus locoregional hyperthermia: An effective treatment for patients with recurrent cervical carcinoma in a previously irradiated area. Int J Hyperthermia 23:443–450CrossRefPubMed
9.
Zurück zum Zitat Franckena M, Stalpers LJ, Koper PC et al (2008) Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys 70:1176–1182CrossRefPubMed Franckena M, Stalpers LJ, Koper PC et al (2008) Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys 70:1176–1182CrossRefPubMed
10.
Zurück zum Zitat Gellermann J, Hildebrandt B, Issels R et al (2006) Non-invasive MR-thermography of soft tissue sarcomas during regional hyperthermia: Correlation with response and direct thermometry. Cancer 107:1373–1382CrossRefPubMed Gellermann J, Hildebrandt B, Issels R et al (2006) Non-invasive MR-thermography of soft tissue sarcomas during regional hyperthermia: Correlation with response and direct thermometry. Cancer 107:1373–1382CrossRefPubMed
11.
Zurück zum Zitat Gofrit ON, Shapiro A, Pode D et al (2004) Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 63:466–471CrossRefPubMed Gofrit ON, Shapiro A, Pode D et al (2004) Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 63:466–471CrossRefPubMed
12.
Zurück zum Zitat Haveman J, Rietbroek RC, Geerdink A et al (1995) Effect of hyperthermia on the cytotoxicity of 2’,2’-difluorodeoxycytidine (gemcitabine) in cultered SW1573 cells. Int J Cancer 62:627–630CrossRefPubMed Haveman J, Rietbroek RC, Geerdink A et al (1995) Effect of hyperthermia on the cytotoxicity of 2’,2’-difluorodeoxycytidine (gemcitabine) in cultered SW1573 cells. Int J Cancer 62:627–630CrossRefPubMed
14.
Zurück zum Zitat Issels RD, Lindner LH, Verweij J et al (2010) Neo-adjuvant chemotherap alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 11:561–570CrossRefPubMed Issels RD, Lindner LH, Verweij J et al (2010) Neo-adjuvant chemotherap alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol 11:561–570CrossRefPubMed
15.
Zurück zum Zitat Jones E, Secord AA, Prosnitz LR et al (2006) Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma. Int J Hyperthermia 22:161–172CrossRefPubMed Jones E, Secord AA, Prosnitz LR et al (2006) Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma. Int J Hyperthermia 22:161–172CrossRefPubMed
16.
Zurück zum Zitat Krause SW, Gastpar R, Andreesen C et al (2004) Treatment of colon and lung cancer patients with ex vivo heat shock protein k70-peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin Cancer Res 10:3699–3707CrossRefPubMed Krause SW, Gastpar R, Andreesen C et al (2004) Treatment of colon and lung cancer patients with ex vivo heat shock protein k70-peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin Cancer Res 10:3699–3707CrossRefPubMed
17.
Zurück zum Zitat Lindner LH, Eichhorn ME, Eibl H et al (2004) Novel temperature sensitive liposomes with prolonged circulating time. Clin Cancer Res 10:2168–2178CrossRefPubMed Lindner LH, Eichhorn ME, Eibl H et al (2004) Novel temperature sensitive liposomes with prolonged circulating time. Clin Cancer Res 10:2168–2178CrossRefPubMed
18.
Zurück zum Zitat Maier-Hauff K, Rothe R, Scholz R et al (2007) Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: Results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol 81:53–60CrossRefPubMed Maier-Hauff K, Rothe R, Scholz R et al (2007) Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: Results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol 81:53–60CrossRefPubMed
19.
Zurück zum Zitat Rietbroek RC, Schilthuis MS, Bakker PJM et al (1997) Phase II trial of weekly locoregional hyperthermia and cisplatin in patients with a previously irradiated recurrent carcinoma of the uterine cervix. Cancer 79:935–943CrossRefPubMed Rietbroek RC, Schilthuis MS, Bakker PJM et al (1997) Phase II trial of weekly locoregional hyperthermia and cisplatin in patients with a previously irradiated recurrent carcinoma of the uterine cervix. Cancer 79:935–943CrossRefPubMed
20.
Zurück zum Zitat Romanowski R, Schött C, Issels R et al (1993) Regionale Hyperthermie mit systemischer Chemotherapie bei Kindern und Jugendlichen: Durchführbarkeit und klinische Verläufe bei 34 intensiv vorbehandelten Patienten mit prognostisch ungünstigen Tumorerkrankungen. Klin Padiatr 205:249–256CrossRefPubMed Romanowski R, Schött C, Issels R et al (1993) Regionale Hyperthermie mit systemischer Chemotherapie bei Kindern und Jugendlichen: Durchführbarkeit und klinische Verläufe bei 34 intensiv vorbehandelten Patienten mit prognostisch ungünstigen Tumorerkrankungen. Klin Padiatr 205:249–256CrossRefPubMed
21.
Zurück zum Zitat Towle LR (1994) Hyperthermia and drug resistance. In: Urano M, Douple E (Hrsg) Hyperthermia and oncology, Bd 4. VSP,Utrecht, S 91–113 Towle LR (1994) Hyperthermia and drug resistance. In: Urano M, Douple E (Hrsg) Hyperthermia and oncology, Bd 4. VSP,Utrecht, S 91–113
22.
Zurück zum Zitat Bree C van, Beumer C, Rodermond HM et al (1999) Effectiveness of 2’,2’-difluorodeoxycytidine (gemcitabine) combined with hyperthermia in rat R-1 rhabdomyosarcoma in vitro and in vivo. Int J Hyperthermia 15:549–556CrossRefPubMed Bree C van, Beumer C, Rodermond HM et al (1999) Effectiveness of 2’,2’-difluorodeoxycytidine (gemcitabine) combined with hyperthermia in rat R-1 rhabdomyosarcoma in vitro and in vivo. Int J Hyperthermia 15:549–556CrossRefPubMed
23.
Zurück zum Zitat Zee J van der, Gonzalez Gonzalez D, Rhoon G van et al (2000) Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective randomized, multicenter trial. Lancet 355:1119–1125CrossRefPubMed Zee J van der, Gonzalez Gonzalez D, Rhoon G van et al (2000) Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective randomized, multicenter trial. Lancet 355:1119–1125CrossRefPubMed
24.
Zurück zum Zitat Wessalowski R, Blohm M, Calaminus G et al (1997) Treatment results in children and adolescents with loco-regional recurrences of abdominal germ cell tumors (GCTs): a pilot-study with PEI chemotherapy and regional deep hyperthermia (RHT) in comparison to a matched cohort. Klin Padiatr 209:250–256CrossRefPubMed Wessalowski R, Blohm M, Calaminus G et al (1997) Treatment results in children and adolescents with loco-regional recurrences of abdominal germ cell tumors (GCTs): a pilot-study with PEI chemotherapy and regional deep hyperthermia (RHT) in comparison to a matched cohort. Klin Padiatr 209:250–256CrossRefPubMed
25.
Zurück zum Zitat Wessalowski R, Schneider DT, Mils O et al (2003) An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin Padiatr 215:303–309CrossRefPubMed Wessalowski R, Schneider DT, Mils O et al (2003) An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin Padiatr 215:303–309CrossRefPubMed
26.
Zurück zum Zitat Witjes JA, Hendricksen K, Gofrit O et al (2009) Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo® working party. World J Urol 27:319–324CrossRef Witjes JA, Hendricksen K, Gofrit O et al (2009) Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo® working party. World J Urol 27:319–324CrossRef
Metadaten
Titel
Stellenwert der Hyperthermie im Rahmen der medikamentösen Tumortherapie
verfasst von
PD Dr. L.H. Lindner
R.D. Issels
Publikationsdatum
01.11.2010
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 11/2010
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-010-1899-2

Weitere Artikel der Ausgabe 11/2010

Der Onkologe 11/2010 Zur Ausgabe

Einführung zum Thema

Zwischen Hoffen und Bangen

CME Weiterbildung · Zertifizierte Fortbildung

Induktionschemotherapie bei Kopf-Hals-Tumoren

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.